The microtubule-targeting agents, PBOX-6 [pyrrolobenzoxazepine 7-[(dimethylcarbamoyl)oxy] - 6-(2-naphthyl)pyrrolo-[2,1-d] (1,5)-benzoxazepine] and paclitaxel, induce nucleocytoplasmic redistribution of the peptidyl-prolyl isomerases, cyclophilin A and pin1, in malignant hematopoietic cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 1, 2009, Pages 38-47

  Bane, Fiona T ^a   Bannon, John H ^a   Pennington, Stephen R ^a   Campaini, Giuseppe ^b   Williams, D Clive ^c   Zisterer, Daniela M ^c   Mc Gee, Margaret M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF SIENA   (Italy)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHILIN A; PACLITAXEL; PBOX 6; PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE PIN1; PYRROLOBENZOXAZEPINE 7 DIMETHYLCARBAMOYLOXY 6 (2 NAPHTHYL)PYRROLO[2,1 D](1,5)BENZOXAZEPINE; SERINE PROTEINASE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL MEMBRANE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOSOL; ENZYME LOCALIZATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROTUBULE; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL DIVISION; CELL MEMBRANE; CELL NUCLEUS; CYCLOPHILIN A; CYTOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; G2 PHASE; HEMATOLOGIC NEOPLASMS; HUMANS; HYDROLYSIS; MICROTUBULES; MONOCYTES; OXAZEPINES; PACLITAXEL; PEPTIDE MAPPING; PEPTIDYLPROLYL ISOMERASE; PYRROLES; SILVER STAINING; TRYPSIN;

EID: 63849227164     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.148130     Document Type: Article

References (39)

1. Ansari H, Greco G, and Luban J (2002) Cyclophilin a peptidyl-prolyl isomerase activity promotes ZPR1 nuclear export. Mol Cell Biol 22:6993-7003.
2. Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP, and Wang DG (2004) Prevalent overexpression of prolyl isomerase pinl in human cancers. Am J Pathol 164:17271737.
3. Bhat KM and Setaluri V (2007) Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res 13:2849-2854.
4. Boone CW, Ford LE, Bond HE, Stuart DC, and Lorenz D (1969) Isolation of plasma membrane fragments from HeLa cells. J Cell Biol 41:378-392.
5. Brazin KN, Mallis RJ, Fulton DB, and Andreotti AH (2002) Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc Natl Acad Sci USA 99:1899-1904.
6. Choi KJ, Piao YJ, Lim MJ, Kim JH, Ha J, Choe W, and Kim SS (2007) Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia - and cisplatin-induced cell death. Cancer Res 67:3654-3662.
7. Ciallela JR, Saporito M, Lund S, Leist M, Hasseldam H, McGann N, Smith CS, Bozyczko-Coyne D, and Flood DG (2005) CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-α release from lipopolysaccharide-treated cells and mice. Eur J Pharmacol 515:179-187.
8. Ellenberg J and Lippincott-Schwartz J (1999) Dynamics and mobility of nuclear envelope proteins in interphase and mitotic cells revealed by green fluorescent protein chimeras. Methods 19:362-372.
9. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, and Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876 - 880.
10. Greene LM, Campiani G, Lawler M, Williams DC, and Zisterer DM (2008) BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol 73:419 - 430.
11. Greene LM, Fleeton M, Mulligan J, Gowda C, Sheahan BJ, Atkins GJ, Campiani G, Nacci V, Lawler M, Williams DC, and Zisterer DM (2005) The pyrrolo-1,5 - benzoxazepine, PBOX-6, inhibits the growth of breast cancer cells in vitro independent of estrogen receptor status and inhibits breast tumour growth in vivo. Oncol Rep 14:1357-1363.
12. Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, and Zisterer DM (2007) STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and - resistant Bcr-Abl-positive human chronic myeloid leukemia cells. JPharma - col Exp Ther 321:288-297.
13. Hantschel O and Superti-Furga G (2004) Regulation of the c-Abl and Bcr-Abl ty - rosine kinases. Nat Rev Mol Cell Biol 5:33-44.
14. Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF, and Patz EF Jr (2005) Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res 65:8853-8860.
15. Johansson B, Fioretos T, and Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76-94.
16. Jordens J, Janssens V, Longin S, Stevens I, Martens E, Bultynck G, Engelborghs Y, Lescrinier E, Waelkens E, Goris J, et al. (2006) The protein phosphatase 2A phosphatase activator is a novel peptidyl-prolyl cis/trans-isomerase. J Biol Chem 281:6349-6357.
17. F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, and Altieri DC (1998) Control ofapoptosis and mitoticspindle checkpointbysurvivin. Nature396:580-584.
18. M, Zhai Q, Bharadwaj U, Wang H, Li F, Fisher WE, Chen C, and Yao Q (2006) Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 106:2284-2294.
19. Liu XM, Wang LG, Kreis W, Budman DR, and Adams LM (2001) Differential effect of vinorelbine versus paclitaxel on ERK2 kinase activity during apoptosis in MCF-7 cells. Br J Cancer 85:1403-1411.
20. Lu KP, Finn G, Lee TH, and Nicholson LK (2007) Prolyl cis-trans isomerization as a molecular timer. Nat Chem Biol 3:619 - 629.
21. Gee MM, Campiani G, Ramunno A, Nacci V, Lawler M, Williams DC, and Zisterer DM (2002) Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells. J Biol Chem 227:18383-18389.
22. Gee MM, Greene LM, Ledwidge S, Campiani G, Nacci V, Lawler M, Williams DC, and Zisterer DM (2004) Selective induction of apoptosis by the pyrrolo-1,5 - benzoxazepine 7-[[dimethylcarbamoyl]oxy]-6-(2-naphthyl)pyrrolo-[2,1-d] (1,5) - benzoxazepine (PBOX-6) in leukemia cells occurs via the c-Jun NH2-terminal kinase-dependent phosphorylation and inactivation of Bcl-2 and Bcl-XL. J Pharmacol Exp Ther 310:1084-1095.
23. 2+-dependent acidic endonuclease activity. Apoptosis 11:1473-1487.
24. Mollinedo F and Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8:413-450.
25. Mulligan JM, Greene LM, Cloonan S, Mc Gee MM, Onnis V, Campiani G, Fattorusso C, Lawler M, Williams DC, and Zisterer DM (2006) Identificationoftubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines. Mol Pharmacol 70: 60-70.
26. Nicholson LK and Lu KP (2007) Prolyl cis-trans isomerization as a molecular timer in Crk signaling. Mol Cell 25:483-485.
27. Pathan N, Aime-Sempe C, Kitada S, Haldar S, and Reed JC (2001) Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1. Neoplasia 3:70 - 79.
28. Puthalakath H, Huang DC, O'Reilly LA, King SM, and Strasser A (1999) The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 3:287-296.
29. Sawyers CL, Hochhaus A, Feldman E, Goldman JM., Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, et al. (2002). Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530 - 3539.
30. Shen M, Stukenberg PT, Kirschner MW, and Lu KP (1998) The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphopro - teins. Genes Dev 12:706-720.
31. Stone AA and Chambers TC (2000) Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. ExpCell Res 254:110-119.
32. Stukenberg PT and Kirschner MW (2001) Pin1 acts catalytically to promote a conformational change in Cdc25. Mol Cell 7:1071-1083.
33. Verma NK, Dempsey E, Conroy J, Olwell P, Mcelligott AM, Davies AM, Kelleher D, Butini S, Campiani G, Williams DC, et al. (2008) A new microtubule-targeting compound PBOX-15 inhibits T-cell migration via post-translational modifications of tubulin. J Mol Med 86:457-469.
34. Wang P and Heitman J (2005) The cyclophilins. Genome Biol 6:226.
35. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, and Lu KP (2001) Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 20:3459-3472.
36. Vrzal R, Daujat-Chavanieu M, Pascussi JM, Ulrichova J, Maurel P, and Dvorak Z (2008) Microtubules-interfering agents restrict aryl hydrocarbon receptor - mediated CYP1A2 induction in primary cultures of human hepatocytes via c-jun-N-terminal kinase and glucocorticoid receptor. Eur J Pharmacol 58:244-254.
37. Yang L, Guan T, and Gerace L (1997) Integral membrane proteins of the nuclear envelope are dispersed throughout the endoplasmic reticulum during mitosis. JCell Biol 137:1199-1210.
38. Yeh ES and Means AR (2007) PIN1, the cell cycle and cancer. Nat Rev Cancer 7:381-388.
39. Zhou Jand Giannakakou P (2005) Targetingmicrotubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5:65-71.